Figure 3.

SB203580 protected Atm^−/− cerebella Purkinje cells. (A): After treatment, cerebellum sections of adult (postnatal day 90 [P90]) Atm^+/+, Atm^−/−, and Atm^−/−+SB mice were stained with H&E to display cerebellum cytoarchitecture. (B): After treatment, cerebellum sections of adult (P90) Atm^+/+, Atm^−/−, and Atm^−/−+SB mice were stained with an antibody against calbindin to detect Purkinje cells. Scale bar = 20 μm. (C): Purkinje cell numbers along the PCL of cerebellar hemispheres of adult (P90) Atm^+/+, Atm^−/−, and Atm^−/−+SB mice were counted. Values represent percentage of Atm^+/+ Purkinje cell number ± SD (three independent counting of 10 fields; ***, p < .001; *, p < .05). (D): Protein levels of the Purkinje cell-specific protein calbindin were determined by Western blot analysis using protein extracts from cerebellar tissue of adult (P90) Atm^+/+, Atm^−/−, and Atm^−/−+SB mice. (E): Expression of calbindin mRNA was determined by quantitative reverse transcription-polymerase chain reaction using total RNA from cerebellar tissue of adult (P90) Atm^+/+, Atm^−/−, and Atm^−/−+SB mice. Probing for gapdh was used as an internal control. Abbreviations: Atm^+/+, PBS-treated Atm^+/+; Atm^−/−, PBS-treated Atm^−/−; Atm^−/−+SB, SB203580-treated Atm^−/−; Calb, calbindin; GL, granular layer; H&E, hematoxylin/eosin; ML, molecular layer; PCL, Purkinje cell layer; SB, SB203580; WT, wild-type.